INTRODUCTION {#S1}
============

Imatinib mesylate, a tyrosine kinase inhibitor, is a targeted therapy for chronic myelogenous leukemia (CML).^[@R1]^ Its function is related to inhibition of multiple tyrosine kinases such as Bcr- Abl, Platelet-derived growth factor and C kit.^[@R2]^ Several side effects have been ascribed to imatinib; of them the most common is peripheral edema.^[@R3]-[@R6]^ Tyrosine kinase inhibitors were shown to cause not only thyroid dysfunction in some cases^[@R7]^ but also may increase the levothyroxine dose in thyroidectomized patients.^[@R8]^ However, these findings are mostly based on retrospective studies. Here, we assessed the effects of imatinib therapy on thyroid function tests in a prospective manner.

MATERIALS AND METHODS {#S2}
=====================

16 (9 male and 7 female) newly diagnosed cases of Philadelphia chromosome positive CML in chronic phase were recruited in this prospective study. Patients receiving medications that may affect thyroid function including steroids, anticonvulsants e.g. phenytoin, iodine and iodine containing drugs, rifampin and salicylates were excluded from the study. Those with any previous thyroid disorders, hepatic dysfunction, renal dysfunction and any other major systemic illnesses as well as acute and chronic infections were also excluded.

Physical examination including careful thyroid examination was performed at each visit and 5cc of whole blood was obtained from all eligible patients. Sera were stored at -80°C until further analysis. Imatinib was prescribed at 300 mg/day and patients were evaluated at 4 and 12 weeks after treatment. TSH, Free T4, Free T3, Anti thyroid peroxidase (Anti TPO), and Anti thyroglobulin (Anti Tg) were measured by Chemiluminescence assay (CLIA) just before and after 4 and 12 weeks after initiation of treatment.

Statistical analyses were performed using SPSS software, version 18. Data presented as the mean±SE and Wilcoxon signed- rank test was used to compare related parameters with baseline at various times.

The study protocol was approved by local medical ethics committee and informed consent was obtained from all of the participants.

RESULTS {#S3}
=======

In this prospective study, 16 eligible patients with newly diagnosed CML and a mean age of 29±5 years were enrolled. 9 cases were male (57.1%) and 7 cases were female (42.9%). Changes in thyroid function tests were compared with baseline at 4 and 12 weeks after imatinib therapy. There was statistically significant decrease in TSH level (P=0.002) at week 12 ([Fig 1](#F1){ref-type="fig"}) and significant increase in Free T3 at week 4 (P=0.012) and 12 (P=0.007) ([Fig 2](#F2){ref-type="fig"}) ([Table 1](#T1){ref-type="table"}). There were no significant changes in FT4 (P=0.650) and Anti TPO (P=0.600) during 12 weeks of treatment with imatinib ([Table 1](#T1){ref-type="table"}).

DISCUSSION {#S4}
==========

Although our results showed statistically significant changes in TSH, FT4 and anti-thyroglobulin during study period, these changes were within normal laboratory values. In addition, none of the patients clinically developed signs of thyroid dysfunction which further denotes these alterations are not clinically important.

In a similar study by Dora et al., in 2008, all of the cases of CML on imatinib therapy followed for more than six months, none of them developed thyroid dysfunction.^[@R9]^ In that study, levels of TSH, Free T3, Free T4, Anti TPO, before and during imatinib therapy were normal. However, Degroot et al., in 2005 showed 59% and 63% changes in FT4 and FT3 in patients with thyroid cancer who received imatinib.^[@R8]^ In another study, imatinib therapy increased dose of levothyroxine in patients with replacement therapy.^[@R10]^ Kim et al., also reported alterations in thyroid function tests in 25% of patients received imatinib.^[@R11]^

More studies were assessed the effects of other tyrosine kinase inhibitors, especially sunitinib on thyroid function. The abnormalities included autoimmune thyroiditis, transient or permanent hypothyroidism and increased dose of levothyroxine.^[@R5],\ [@R11]-[@R14]^

The mechanism of action of tyrosine kinase inhibitors on thyroid was attributed to induction of apoptosis which first manifests as a destructive thyroiditis and then gradually progresses to atrophic hypothyroidism.^[@R5],\ [@R15]^

Although the sample size was a limiting factor in our study, we followed the patients prospectively for more than 12 weeks. This period of follow-up probably suffices to cover the small sample size.

CONCLUSION {#S5}
==========

In contrast to other tyrosine kinase inhibitors, imatinib is not associated with significant clinical adverse effects on thyroid function at least in short-term follow-up.
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###### 

Baseline parameters & changes during imatinib therapy

  Parameter        0 week      4 weeks     P-value   12 weeks    P-value
  ---------------- ----------- ----------- --------- ----------- ---------
  TSH mlu/L        2.13±0.40   2.25±0.70   0.75      1.42±0.35   0.002
  Free T4 pg/ml    1.01±0.06   1.04±0.07   0.19      1.03±0.05   0.65
  Free T3 pg/ml    2.10±0.14   2.58±0.10   0.012     2.67±0.10   0.007
  Anti TPO IU/ml   11.3±7.2    15.3±11.3   0.80      13.5±9.4    0.60
  Anti TG IU/ml    22.8±10.9   22.5±12.2   0.221     18.7±8.70   0.041
